Compare MD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | EYPT |
|---|---|---|
| Founded | 1979 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 1995 | 2005 |
| Metric | MD | EYPT |
|---|---|---|
| Price | $21.09 | $13.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $21.00 | ★ $28.75 |
| AVG Volume (30 Days) | 564.0K | ★ 1.1M |
| Earning Date | 02-19-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $1,922,442,000.00 | $42,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $10.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.84 | $3.91 |
| 52 Week High | $24.99 | $19.11 |
| Indicator | MD | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.94 | 41.74 |
| Support Level | $20.55 | $12.11 |
| Resistance Level | $21.58 | $13.68 |
| Average True Range (ATR) | 0.70 | 1.00 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 42.34 | 34.20 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.